TELA Bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $31.6M
- Price
- $0.647
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.62%
- Volume
- 119.0K
About
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Quick stats
Shares outstanding44.8M
Computed float28.5M
Float / shares63.6%
Cash runway (months)11.7
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001561921
Websitehttps://www.telabio.com
AI Summary
AI-generated1/14
majorbearishearnings
TELA Bio Reports Second Quarter 2026 Financial Results
TELA Bio reported second quarter 2026 revenue of $19.3 million, down 4% from the prior year, with a net loss of $11.3 million widening compared to a loss of $9.9 million in the same period last year.
The company announced the appointment of Heather Getz as CEO and simultaneously withdrew its full-year 2026 revenue guidance as management evaluates strategic direction and focuses on extending cash runway.
Operational highlights included 12% unit volume growth for OviTex and 26% international revenue growth, though these were offset by a decline in OviTex PRS volumes and continued price and mix headwinds.
Red flags
- Full-year 2026 revenue guidance withdrawn
- Revenue declined 4% year-over-year
- Net loss widened to $11.3 million
- CEO transition period